{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "immunotherapy",
      "pancreatic cancer",
      "prevention vaccines"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29860986",
  "DateCompleted": {
    "Year": "2019",
    "Month": "02",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "09",
    "Day": "26"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "04",
        "Day": "30"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.trecan.2018.04.001",
      "S2405-8033(18)30090-6"
    ],
    "Journal": {
      "ISSN": "2405-8025",
      "JournalIssue": {
        "Volume": "4",
        "Issue": "6",
        "PubDate": {
          "Year": "2018",
          "Month": "Jun"
        }
      },
      "Title": "Trends in cancer",
      "ISOAbbreviation": "Trends Cancer"
    },
    "ArticleTitle": "Immunotherapy and Prevention of Pancreatic Cancer.",
    "Pagination": {
      "StartPage": "418",
      "EndPage": "428",
      "MedlinePgn": "418-428"
    },
    "Abstract": {
      "AbstractText": [
        "Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently surpassing breast cancer. A key component of pancreatic cancer's lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T cell infiltration, and a low mutational burden. Although immunotherapies such as checkpoint blockade or engineered T cells have yet to demonstrate efficacy, a growing body of evidence suggests that orthogonal combinations of these and other strategies could unlock immunotherapy in pancreatic cancer. In this Review article, we discuss promising immunotherapies currently under investigation in pancreatic cancer and provide a roadmap for the development of prevention vaccines for this and other cancers."
      ],
      "CopyrightInformation": "Copyright \u00a9 2018 Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19014, USA."
          }
        ],
        "LastName": "Morrison",
        "ForeName": "Alexander H",
        "Initials": "AH"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19014, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA 19014, USA."
          }
        ],
        "LastName": "Byrne",
        "ForeName": "Katelyn T",
        "Initials": "KT"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19014, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA 19014, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19014, USA. Electronic address: rhv@upenn.edu."
          }
        ],
        "LastName": "Vonderheide",
        "ForeName": "Robert H",
        "Initials": "RH"
      }
    ],
    "GrantList": [
      {
        "GrantID": "P30 CA016520",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA169121",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA169123",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "TL1 TR001880",
        "Acronym": "TR",
        "Agency": "NCATS NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, N.I.H., Extramural",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Trends Cancer",
    "NlmUniqueID": "101665956",
    "ISSNLinking": "2405-8025"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cancer Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Cancer Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunotherapy"
    },
    {
      "QualifierName": [
        "immunology",
        "therapy"
      ],
      "DescriptorName": "Pancreatic Neoplasms"
    }
  ]
}